Acquiring Company
argenx SE
Acquired Company
Forte Biosciences
AmsterdamBiotechnologyHealth CareTherapeuticsDescription
On August 27, 2026, argenx SE finalized its acquisition of Forte Biosciences, Inc., integrating the small biotech into its operations. This move enables Forte to advance its dermatology and immunology programs under the larger argenx umbrella. Following the acquisition, trading for Forte Biosciences will be adjusted as it is delisted from several options exchanges.
Don't miss argenx SE's next move
Get an email the moment argenx SE makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Forte Biosciences?
Forte Biosciences was acquired by argenx SE, based in Amsterdam. The deal was reported on September 2, 2026. argenx SE is a biotech company that develops new therapies for severe autoimmune diseases and cancer. Their innovative approach focuses on harnessing the power of the immune system to combat diseases. argenx SE is publicly traded (ARGX) and operates in Biotechnology.
When did argenx SE acquire Forte Biosciences?
argenx SE's acquisition of Forte Biosciences was reported on September 2, 2026. On August 27, 2026, argenx SE finalized its acquisition of Forte Biosciences, Inc., integrating the small biotech into its operations. This move enables Forte to advance its dermatology and immunology programs under the larger argenx umbrella. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Forte Biosciences do?
Forte Biosciences is the company acquired in this transaction. It is publicly traded (FBRX).
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.